ACLX
Arcellx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$115.07
+0.02%Year over year
Reported trailing growth
- Revenue
- -79.4%
- EBITDA
- -99.8%
- EBIT
- -84.0%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -55.1%
- EBITDA
- -99.8%
- EBIT
- -84.0%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025